#1 Clinical Trials Search in Europe

Bintrafusp Alfa

Bintrafusp alfa, also known as M7824, is an innovative drug being studied in clinical trials for the treatment of various types of cancer. This bifunctional fusion protein targets both TGF-β and PD-L1, showing potential in combating advanced and difficult-to-treat cancers. Clinical trials are investigating its efficacy and safety in cancers such as urothelial carcinoma, mesothelioma, cervical cancer, and more.

Table of Contents

What is Bintrafusp Alfa?

Bintrafusp alfa, also known as M7824, is an innovative drug being studied for the treatment of various types of cancer[1]. It is a bifunctional fusion protein, which means it combines two different functions in one molecule. This unique design allows it to target multiple aspects of cancer growth and spread[1].

How Does Bintrafusp Alfa Work?

Bintrafusp alfa works in two main ways to fight cancer:

  1. It blocks a protein called PD-L1, which helps cancer cells hide from the immune system. By blocking PD-L1, bintrafusp alfa helps the immune system recognize and attack cancer cells[1].
  2. It also targets a protein called TGF-beta, which can help cancer cells grow and spread. By blocking TGF-beta, bintrafusp alfa may slow down or stop cancer growth[1].

This dual action makes bintrafusp alfa a potentially powerful tool in fighting cancer, as it both boosts the immune system’s ability to fight cancer and directly interferes with cancer growth[1].

Cancers Treated with Bintrafusp Alfa

Bintrafusp alfa is being studied for the treatment of several types of cancer, including:

  • Brain metastases: Cancer that has spread to the brain from other parts of the body[1]
  • Urothelial cancer: A type of bladder cancer[2]
  • Malignant pleural mesothelioma: Cancer of the lining of the lungs[3]
  • Cervical cancer: Cancer of the cervix[4]
  • Triple-negative breast cancer: A type of breast cancer that doesn’t respond to common treatments[5]
  • Head and neck squamous cell carcinoma: Cancer in the mouth, throat, or voice box[6]

Clinical Trials and Research

Bintrafusp alfa is currently being studied in several clinical trials to determine its effectiveness and safety. These trials are investigating its use in different stages of cancer and in combination with other treatments. Some key areas of research include:

  • Using bintrafusp alfa before surgery (neoadjuvant therapy) in bladder cancer and head and neck cancer[7][6]
  • Treating advanced cancers that have not responded to other treatments[2][4]
  • Combining bintrafusp alfa with other cancer drugs to improve effectiveness[1]

Administration and Dosage

Bintrafusp alfa is typically given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein. The most common dosage being studied is 1200 mg every two weeks[2][4]. However, the exact dosage and schedule may vary depending on the specific cancer being treated and the clinical trial protocol.

Treatment usually continues until the cancer progresses, unacceptable side effects occur, or the patient decides to stop. In some studies, treatment may continue for up to two years if it’s helping the patient[2].

Potential Side Effects

As with any cancer treatment, bintrafusp alfa can cause side effects. These are being closely monitored in clinical trials. Some potential side effects may include:

  • Infusion-related reactions
  • Immune-related side effects
  • Skin reactions
  • Bleeding events
  • Anemia (low red blood cell count)[4]

It’s important to note that not all patients will experience these side effects, and the severity can vary. Researchers are working to understand and manage these side effects to make treatment as safe as possible.

Future Prospects

Bintrafusp alfa represents a new approach to cancer treatment, combining immunotherapy with targeted therapy. While it’s still in the research phase, early results have shown promise in several types of cancer[2][4].

Ongoing research aims to determine which patients are most likely to benefit from bintrafusp alfa and how it can be most effectively used. This includes studying biomarkers (biological indicators) that might predict response to treatment[1].

As research continues, bintrafusp alfa may become an important new option for cancer patients, particularly those who haven’t responded to other treatments. However, it’s important to remember that more study is needed before it can be widely used outside of clinical trials.

Aspect Details
Drug Name Bintrafusp alfa (also known as M7824)
Mechanism of Action Bifunctional fusion protein targeting TGF-β and PD-L1
Cancer Types Studied Urothelial carcinoma, mesothelioma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, biliary tract cancer
Administration Intravenous infusion, typically 1200 mg every 2 weeks
Primary Outcomes Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS)
Secondary Outcomes Duration of Response (DOR), Safety and Tolerability, Quality of Life
Trial Phases Phase I, Phase II
Notable Approaches Neoadjuvant therapy, monotherapy, combination therapy
Safety Monitoring Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs)

FAQ

  • What is Bintrafusp alfa? Bintrafusp alfa, also known as M7824, is a bifunctional fusion protein that targets both TGF-β and PD-L1. It is being studied as a potential treatment for various types of cancer in clinical trials.
  • What types of cancer is Bintrafusp alfa being tested for? Bintrafusp alfa is being studied in clinical trials for several types of cancer, including urothelial carcinoma, mesothelioma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and biliary tract cancer.
  • How is Bintrafusp alfa administered? Bintrafusp alfa is typically administered as an intravenous infusion. In most trials, it is given at a dose of 1200 mg every two weeks, although some studies may use different dosing schedules.
  • What are the main goals of the clinical trials studying Bintrafusp alfa? The main goals of these clinical trials are to evaluate the efficacy, safety, and tolerability of Bintrafusp alfa in treating various cancers. Researchers are looking at outcomes such as objective response rate, progression-free survival, overall survival, and the incidence of adverse events.
  • Are there any known side effects of Bintrafusp alfa? As with any drug in clinical trials, side effects are being closely monitored. Some potential side effects may include infusion-related reactions, immune-related adverse events, and skin reactions. The full safety profile is still being established through ongoing clinical studies.

Ongoing Clinical Trials on Bintrafusp Alfa

  • Study on Bintrafusp Alfa with Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma

    Not recruiting

    2 1 1
    Investigated drugs:
    The Netherlands

  • Study of Bintrafusp Alfa and Doxorubicin Hydrochloride for Adults with Advanced Soft-Tissue Sarcoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Bintrafusp alfa: A bifunctional fusion protein that targets both TGF-β and PD-L1, being studied as a potential treatment for various types of cancer.
  • TGF-β: Transforming Growth Factor Beta, a protein that plays a role in cell growth and division.
  • PD-L1: Programmed Death-Ligand 1, a protein that helps keep immune cells from attacking nonharmful cells in the body.
  • Urothelial carcinoma: A type of cancer that typically occurs in the urinary system, including the bladder and related organs.
  • Mesothelioma: A type of cancer that develops in the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Neoadjuvant therapy: Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery.
  • Pathological response: The degree to which a tumor has responded to treatment, as determined by examining tissue samples under a microscope.
  • Intravenous infusion: The administration of a fluid or medication directly into a vein.
  • Monotherapy: The use of a single drug to treat a particular disorder or disease.
  • Immunoglobulin G1 (IgG1): A type of antibody that plays a crucial role in the immune response against pathogens and cancer cells.

References

  1. https://clinicaltrials.gov/study/NCT04789668
  2. https://clinicaltrials.gov/study/NCT04349280
  3. https://clinicaltrials.gov/study/NCT05005429
  4. https://clinicaltrials.gov/study/NCT04246489
  5. https://clinicaltrials.gov/study/NCT04489940
  6. https://clinicaltrials.gov/study/NCT04428047
  7. https://clinicaltrials.gov/study/NCT04878250